ENDRA Life Sciences Inc. (NDRA) analyst actions
Rating and price-target actions on NDRA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NDRA overview →
1 measured NDRA analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value | Press release | -2.42% | +13.64% |
Keep exploring
More NDRA: earnings → · SEC filings → · NDRA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Harvard Bioscience, Inc. (HBIO) | 183 | -0.30% | 43% |
| ELEKTA B SHS UNSP/ADR (EKTAY) | 182 | 0.00% | 17% |
| Cocrystal Pharma, Inc. (COCP) | 180 | 0.00% | 48% |
| BIO BLAST PHARMA LTD ORDINARY (ORPN) | 180 | 0.00% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.